Organisation paid for research Program year 2022 Source: CMS Open Payments

Acrc Studies, LLC

Neither a doctor nor a teaching hospital

Research payments

$405,697

25 payments

Through program year 2022, Acrc Studies, LLC is reported as receiving $405,697 in research payments, across 25 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2022	Research	$86,420	7
2021	Research	$229,346	12
2020	Research	$89,930	6

Breakdown

Who paid Research payments · program years 2020–2022

Eli Lilly and Company $399,232 22 payments
Ucb SA $6,465 3 payments

Studies the money was for Research payments · program years 2020–2022

A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis $105,090 3 payments
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus $90,738 2 payments
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (Sle) $49,480 2 payments
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-To-Severe Atopic Dermatitis $47,594 3 payments
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis $44,994 2 payments
A Randomized, Controlled Pragmatic Phase 3B/4 Study of Baricitinib in Patients With Rheumatoid Arthritis $40,143 4 payments
A Phase 3, 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-To-Severe Atopic Dermatitis $20,468 2 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus $5,497 2 payments
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Sy $968 1 payment
A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Galcanezumab Versus Rimegepant in Adult Participants With Episodic Migraine $585 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.